Talk to your pharmacist for more details. Before using this medicine, consult your doctor or pharmacist if you have: If you have lost too much body water become dehydrated , your doctor will correct that condition first before starting treatment with desmopressin.
Limit alcohol because it can interfere with how well desmopressin works. The doctor may need to stop or adjust desmopressin treatment, especially in children and older adults. Kidney function declines as you grow older. Discuss the risks and benefits with your doctor. Consult your doctor before breast-feeding.
Store at room temperature between degrees F degrees C away from light and moisture. Do not store in the bathroom. Keep all medicines away from children and pets. Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product. Desmopressin is used to control the amount of urine your kidneys make.
Normally, the amount of urine you make is controlled by a certain substance in the body called vasopressin. Laboratory Tests Central Diabetes Insipidus Laboratory tests for monitoring the patient with central diabetes insipidus or post-surgical or head trauma-related polyuria and polydipsia include urine volume and osmolality. In some cases, measurements of plasma osmolality may be useful. The concomitant administration of drugs that may increase the risk of water intoxication with hyponatremia, e.
Carcinogenicity, Mutagenicity, Impairment of Fertility Studies with DDAVP have not been performed to evaluate carcinogenic potential, mutagenic potential or effects on fertility. Pregnancy Category B Fertility studies have not been done. Teratology studies in rats and rabbits at doses from 0. There are, however, no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Several publications where desmopressin acetate was used in the management of diabetes insipidus during pregnancy are available; these include a few anecdotal reports of congenital anomalies and low birth weight babies.
However, no causal connection between these events and desmopressin acetate has been established. A fifteen year Swedish epidemiologic study of the use of desmopressin acetate in pregnant women with diabetes insipidus found the rate of birth defects to be no greater than that in the general population; however, the statistical power of this study is low.
As opposed to preparations containing natural hormones, desmopressin acetate in antidiuretic doses has no uterotonic action and the physician will have to weigh the possible therapeutic advantages against the possible risks in each case. Nursing Mothers There have been no controlled studies in nursing mothers.
A single study in postpartum women demonstrated a marked change in plasma, but little if any change in assayable DDAVP in breast milk following an intranasal dose of 0. It is not known whether the drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when DDAVP is administered to nursing mothers.
Pediatric Use Central Diabetes Insipidus DDAVP Tablets desmopressin acetate have been used safely in pediatric patients, age 4 years and older, with diabetes insipidus for periods up to 44 months. In younger pediatric patients the dose must be individually adjusted in order to prevent an excessive decrease in plasma osmolality leading to hyponatremia and possible convulsions; dosing should start at 0. Use of DDAVP Tablets in pediatric patients requires careful fluid intake restrictions to prevent possible hyponatremia and water intoxication.
Primary Nocturnal Enuresis DDAVP Tablets have been safely used in pediatric patients age 6 years and older with primary nocturnal enuresis for up to 6 months. Some patients respond to a dose of 0. No increase in the frequency or severity of adverse reactions or decrease in efficacy was seen with an increased dose or duration.
The dose should be individually adjusted to achieve the best results. Because many drugs are excreted in human milk, caution should be exercised when DDAVP desmopressin acetate tablets is administered to nursing mothers. DDAVP Tablets desmopressin acetate have been used safely in pediatric patients, age 4 years and older, with diabetes insipidus for periods up to 44 months. In younger pediatric patients the dose must be individually adjusted in order to prevent an excessive decrease in plasma osmolality leading to hyponatremia and possible convulsions; dosing should start at 0.
Use of DDAVP desmopressin acetate tablets Tablets in pediatric patients requires careful fluid intake restrictions to prevent possible hyponatremia and water intoxication. DDAVP desmopressin acetate tablets Tablets have been safely used in pediatric patients age 6 years and older with primary nocturnal enuresis for up to 6 months. Some patients respond to a dose of 0. No increase in the frequency or severity of adverse reactions or decrease in efficacy was seen with an increased dose or duration.
The dose should be individually adjusted to achieve the best results. Clinical studies of DDAVP desmopressin acetate tablets Tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
Other reported clinical experience has not identified differences in responses between the elderly and younger patients.
In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. Fluid restriction should be discussed with the patient.
In case of overdose, the dose should be reduced, frequency of administration decreased, or the drug withdrawn according to the severity of the condition. The patient should be observed and treated with appropriate symptomatic therapy. An oral LD50 has not been established. Oral doses up to 0. DDAVP desmopressin acetate tablets is contraindicated in patients with hyponatremia or a history of hyponatremia.
Dose response studies in patients with diabetes insipidus have demonstrated that oral doses of 0. In most patients, doses of 0. With doses of 0.
Tags: buy requip 0.25mg cheapest generic cialis no prescription
© Copyright 2017 DDAVP Tablets mg and mg - Patient Information Leaflet (PIL) - (eMC).